ArticlePharmacoEconomics2006
Costs of inflammatory bowel disease in Germany.
Article in PharmacoEconomics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 5 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.Journal of Crohn's & colitis · 2024Pooled it
- Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.Alimentary pharmacology & therapeutics · 2021Pooled it
- Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data.BMC gastroenterology · 2019Pooled it
- The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review.Digestive diseases and sciences · 2015Pooled it
- Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2011Pooled it
- Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2011Trial
- Growing old at home - a randomized controlled trial to investigate the effectiveness and cost-effectiveness of preventive home visits to reduce nursing home admissions: study protocol [NCT00644826].BMC public health · 2008Trial
- Addressing real-world data gaps: estimating the uk population cost of crohn's disease and ulcerative colitis using a flexible cost-of-illness model informed by the optimal patient journey and IBDUK patient survey 2023.BMC health services research · 2026Article
- Cost-of-illness analysis of ulcerative colitis patients treated with biological therapy: a prospective observational study in Iran.BMC health services research · 2025Observational
- Clinical Utility of Disease Activity Indices in Predicting Short-Term Response to Biologics in Patients with Ulcerative Colitis.Journal of clinical medicine · 2024Article
- Out-of-pocket expenses of patients with inflammatory bowel disease: a comparison of patient-reported outcomes across 12 European countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
- Costs of Healthcare for Children with Inflammatory Bowel Diseases (IBD) in Poland.Children (Basel, Switzerland) · 2023Article
- The cost of illness analysis of inflammatory bowel disease.BMC gastroenterology · 2023Article
- Development and test-retest reliability of a new, self-report questionnaire assessing healthcare use and personal costs in people with inflammatory bowel disease: the Inflammatory Bowel Disease Resource Use Questionnaire (IBD-RUQ).Frontline gastroenterology · 2023Article
- Women's Earnings are more Affected by Inflammatory Bowel Disease than Men's: A Register-Based Swedish Cohort Study.Journal of Crohn's & colitis · 2021Article
- Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany.Inflammatory intestinal diseases · 2021Article
- Direct costs of inflammatory bowel diseases in a Finnish tertiary-level clinic.Frontline gastroenterology · 2021Article
- Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience.United European gastroenterology journal · 2019Article
- The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.Journal of the Canadian Association of Gastroenterology · 2019Article
- Time between suspected and confirmed diagnoses of Crohn's disease and ulcerative colitis in patients followed in gastroenterological practices in Germany.International journal of colorectal disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInflammatory bowel disease (IBD) is a chronic condition that afflicts young adults in their economically productive years. The goal of this study was to determine the costs of IBD in Germany from a societal perspective, using cost diaries.
methodsMembers of the German Crohn's Disease and Ulcerative Colitis Association who had IBD were recruited by post, and those who agreed to participate documented their IBD-associated costs prospectively in a diary over 4 weeks. They documented their use of healthcare facilities, medications, sick leave and out-of-pocket expenditures, as well as general demographic information, the status and history of their IBD, and long-term disability. Item costs were calculated according to national sources. Cost data were calculated using non-parametric bootstrapping and presented as mean costs (year 2004) over 4 weeks.
resultsThe cost diaries were returned by 483 subjects (Crohn's disease: n = 241, ulcerative colitis: n = 242) with a mean age of 42 years and an average disease duration of 13 years (SD +/- 8.09). The cost diaries were regarded as 'easy to complete' by 89% of participants. The mean 4-week costs per subject were 1,425 Euros(95% CI 1201, 1689) for Crohn's disease and 1,015 Euros(95% CI 832, 1258) for ulcerative colitis. Of the total costs for Crohn's disease, 64% were due to indirect costs such as early retirement or sick leave and 32% were due to direct medical costs. In contrast, of the total costs for ulcerative colitis, 41% were due to direct medical costs and 54% to indirect costs.
conclusionsThis is the first comprehensive cost study for Crohn's disease and ulcerative colitis in Germany. The most important economic factors that influenced the cost profiles of both diseases were the long-term productivity losses due to an ongoing inability to work and the cost of medications. Results indicate significant cost differences between Crohn's disease and ulcerative colitis. This data provides initial cost estimates that can be analysed further with respect to cost determinants and disease-specific costs in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.